The CTLA-4 blocker tremelimumab was effective in approximately 17.6% of HCC patients with a hepatitis C virus infection, while the progression time was about 6.48 months (Sangro et al., 2013). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.